Organization (Industry)
Alimera Sciences (Germany)
ClinicalTrials.gov lists Alimera Sciences (Germany) as lead sponsor of 12 trials. It has 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Alimera Sciences (Germany): 12 lead-sponsored trials and 2 legal-entity registrations. Part of ANI PHARMACEUTICALS INC.
Disease areas (11)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Macular Degeneration | 3 |
| Diabetes Mellitus | 1 |
| Diabetic Retinopathy | 1 |
| Geographic Atrophy | 1 |
| Macular Edema | 1 |
Showing 5 of 11 disease areas.
Trials by start year as sponsor or collaborator (11)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 1 |
| 2022 | 1 |
| 2020 | 1 |
| 2015 | 1 |
| 2014 | 1 |
| 2013 | 2 |
| 2011 | 1 |
| 2009 | 1 |
| 2008 | 2 |
Showing 10 of 11 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Fluocinolone Acetonide | 6 |
| Fluocinolone Acetonide Intravitreal Implant 0.18 mg | 1 |
| fluocinolone acetonide 190 micrograms | 1 |
| Iluvien 0.19 MG Drug Implant | 1 |
| ILUVIEN 0.19 MG | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| not enough data | 0 of 1 on time (n=1) |
Journals published in (4)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The British journal of ophthalmology | 2 |
| Current medical research and opinion | 1 |
| Ophthalmic surgery, lasers & imaging retina | 1 |
| The Cochrane database of systematic reviews | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 4 | 1 | 2022-08-02 |
Financing and grant events (2)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2023-03-24 | Private placement | 81,000,000 | Form d |
| 2021-04-14 | Private placement | 10,000,000 | Form d |
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
Manufacturing and distribution sites (1)
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Alimera Sciences, Inc. | Baudette, US | FDA |
Organization relationships (1)
| Related organization | Relationship | Evidence |
|---|---|---|
| CBCC Global Research | Co sponsors trial with | 1 |
Latest dated events (23)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2024-08-31 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2024-03-21 | FDA inspection | FDA enforcement (warning and untitled letters, recalls, inspections, import refusals, debarment) |
| 2023-11-21 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2023-03-24 | Private placement | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2022-08-02 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 23 events.
Biomarker capability evidence (14)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| CCDC198 | Trial sponsor | Named in trial inclusion criteria |
| VEGFA | Trial sponsor | Named in trial inclusion criteria |
| UCN3 | Trial sponsor | Named in trial exclusion criteria |
| UCN3 | Trial sponsor | Named in trial exclusion criteria |
| VEGFA | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 14 evidence rows.
On Scientist.com
Alimera Sciences (Germany) is listed as a research supplier in the Scientist.com network.
Service areas
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry...
Show the full description
Alimera Sciences (NASDAQ: ALIM), founded in June 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in our aging populations. Our commitment to retina specialists and their patients is manifest in our product portfolio designed to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion.
Alimera Sciences’ management team has a strong track record of product discovery, development and revenue growth in the ophthalmic pharmaceutical industry and are dedicated and focused to making Alimera a leading ophthalmic biopharmaceutical company. Our team has demonstrated expertise through the extensive development and commercialization of ophthalmic products. Our strategy behind Alimera is to:
Bring to market ILUVIEN ®, recently granted marketing authorization in Austria, France, Germany, Portugal, Spain and the United Kingdom as “ILUVIEN ® 190 micrograms intravitreal implant in applicator Fluocinolone Acetonide”, for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies. ILUVIEN is now undergoing the national phase of the review process in Italy. Alimera Sciences is still seeking approval in the United States.
Continue evaluating ILUVIEN for other ophthalmic indications. Learn More
Evaluate the use of NADPH Oxidase inhibitors for ophthalmic diseases
Pursue the development, license or acquisition of rights to potential ophthalmic drug delivery technologies and compounds.
Operate as an ethically driven company, recognizing our responsibility to others and the importance of having a positive impact on those with whom we interact.
- Website
- www.alimerasciences.com
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, active development programs, sec-reported annual financials, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.
Work with Alimera Sciences on Scientist.com
For prices, more details, or to contact Alimera Sciences, visit Scientist.com.
Sign in to Scientist.com to open this supplier in your organization's marketplace.